Xcout Intel
Ratio Therapeutics
Ratio Therapeutics is a clinical-stage pharmaceutical company headquartered in Boston, Massachusetts. The company employs a suite of innovative technologies for the discovery and early clinical development of targeted radiopharmaceuticals.
Subscribe to see Ratio Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Ratio Therapeutics at a glance
Ratio Therapeutics is a biotech company headquartered in United States. It has raised at least $140.7M across the 3 funding rounds on record. Its most recent funding round, Series C, raised $70M in July 2026. Xcout tracks 18 named people at Ratio Therapeutics, including Jack Hoppin, Ph.D. (Chairman, Chief Executive Officer).
Ratio Therapeutics leadership
- Jack Hoppin, Ph.D.Chairman, Chief Executive Officer
- Colin Hayward, M.B. B.S.Chief Medical Officer
- Jacob Hesterman, Ph.D .Chief Data Officer
- Marc Becker, M.B.A, CPAChief Financial and Operating Officer
- Marcel Reichen, Ph.D, M.B.AChief Strategy Officer
- Matthias Friebe, Ph.D.Chief Development Officer
12 more named people on record for Ratio Therapeutics, with roles, board committees and tenure — see the full roster →
Ratio Therapeutics funding rounds
At least $140.7M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $70M | 5 named | |
| Series C | $50.7M | 5 named | |
| Series C | $20M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Ratio Therapeutics news
Investors
Ratio Therapeutics competitors
A few of Ratio Therapeutics's closest competitors — see the full list of competitors and alternatives →
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
BIND Therapeutics, Inc. is a clinical-stage nanomedicine company headquartered in Cambridge, Massachusetts. The company specializes in developing targeted and programmable therapeutics using its proprietary platform to treat various diseases.
Alloy Therapeutics, Inc. is a biotechnology ecosystem company dedicated to democratizing access to antibodies, multispecifics, and genetic modalities, with offices in Waltham and Boston, Massachusetts.
Remix Therapeutics, Inc. is a biotechnology company headquartered in Watertown, Massachusetts. The company specializes in developing novel therapies that alter RNA processing to address serious diseases.
76Bio, Inc. is a biotechnology company founded in 2020 and based in Boston, United States. The company develops therapeutics for patients with life-threatening diseases by pioneering targeted protein degraders.
Get Ratio Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Ratio Therapeutics in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access